Business

Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference

FREMONT, Calif., February 17, 2026--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the TD Cowen 46th Annual Healthcare Conference on Tuesday, March 3, 2026 at the Boston Marriott Copley Place in Boston, MA.

Personalis, Inc.February 17, 20261
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference

About this update from Personalis, Inc.

FREMONT, Calif., February 17, 2026 --( BUSINESS WIRE )--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the TD Cowen 46 th Annual Healthcare Conference on Tuesday, March 3, 2026 at the Boston Marriott Copley Place in Boston, MA. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X ( Twitter ). View source version on businesswire.com: https://www.businesswire.com/news/home/20260217655785/en/ Contacts Investor Relations: Caroline Corner [email protected] 415-202-5678 Media: [email protected]

View stock analysis, news, and events for Personalis, Inc.

Boston Marriott Copley PlacePersonalis, Inc.BUSINESS WIREactive managementcancer managementPersonalisprecision oncology

More from Personalis, Inc.

All Personalis, Inc. news →